Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (SAVE-ICU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04415060
Recruitment Status : Not yet recruiting
First Posted : June 4, 2020
Last Update Posted : June 26, 2020
Sponsor:
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre

Brief Summary:

Around1 in 4 COVID-19 patients suffer lung failure needing life-saving support from a breathing machine. Any patient needing this support requires drugs to keep them sleepy, or "sedated" to be comfortable on this machine. Sedation is made possible by using drugs given through a vein. Unfortunately, these drugs are in short supply worldwide due to the high number of COVID-19 patients needing these machines.

Another way to provide sleep is by using gases that are breathed in. These are used every day in operating rooms to perform surgery. These gases, also called "inhaled agents" can also be used in intensive care units and may have several important benefits for patients and the hospital. Research shows they may reduce swelling in the lung and increase oxygen levels, which allows patients to recover faster and reduce the time spent on a breathing machine. In turn, this allows the breathing machine to be used again for the next sick patient. These drugs may also increase the number of patients who live through their illness. Inhaled agents are widely available and their use could dramatically lesson the pressure on limited drug supplies.

This research is a study being carried out in a number of hospitals that will compare how well patients recover from this illness depending on which type of sedation drug they receive. The plan is to evaluate the number who survive, their time spent on a breathing machine and time in the hospital. This study may show immediate benefits and may provide a cost effective and practical solution to the current challenges caring for patients and the hospital space, equipment and drugs to the greatest benefit. Finally, this trial will be a team of experts in sedation drugs who care for COVID-19 patients who need lifesaving treatments.


Condition or disease Intervention/treatment Phase
Covid19 Drug: Isoflurane Inhalant Product Drug: Sevoflurane inhalant product Phase 3

Detailed Description:

Multicentre open-label, pragmatic, randomized controlled trial and a parallel prospective (non-randomized) cohort study conducted in ICUs and ICU enabled environments caring in critically ill COVID-19 patients.

Participants will be adults who are mechanically ventilated with proven positive or possible COVID-19 disease. All centres will be required to randomize every available patient, as non-randomized participants can be entered into a parallel prospective cohort study to try to obtain the maximum amount of information available from the patients present to our ICUs.

There will be variable randomized ratios of 2:1 or 1:2 to either an intravenous based sedation arm or an inhaled volatile-based sedation arm. This randomization will be dependent on availability of sedative drugs for both arms. Patients who cannot be randomized (secondary to technical or resource issues in some areas of the hospital) will receive intravenous or inhaled sedation as able in their designated unit. Sedation will be administered according to standard sedation practice and in keeping with current guidelines.

Participants will remain within their sedation arms until the primary care team decides to stop sedation. Participants will be followed daily throughout their ICU stay for 30 days after enrollment and then at death or hospital discharge (whichever occurs first).

Clinical information during ICU stay will be obtained from the patient chart, electronic medical records, or hospital databases. Participants will be followed using a provincial or hospital healthcare database to obtain survival, and hospital-free days at 60 days, 90 days and 365 days after enrollment.

After hospital discharge, participants will be followed up at; 3 and 12 months to assess quality of life using the EQ-5D; and to assess disability using the WHODAS 2.0.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 752 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicentre open-label, pragmatic, randomized controlled trial and a parallel prospective (non-randomized) cohort study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study
Estimated Study Start Date : June 15, 2020
Estimated Primary Completion Date : June 15, 2022
Estimated Study Completion Date : June 15, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Inhaled - volatile anesthetic
The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
Drug: Isoflurane Inhalant Product
Isoflurane will be administered using an inhalation device

Drug: Sevoflurane inhalant product
Sevoflurane will be administered using an inhalation device

No Intervention: Standard Care
The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
No Intervention: Non-randomized
In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.



Primary Outcome Measures :
  1. Hospital Mortality [ Time Frame: 2 years ]
    Does the use of inhaled volatile anesthetic-based sedation regimen improve participant hospital mortality as compared to standard intravenous sedation regimen with a 10% difference between groups for 752 participants.

  2. Ventilator-Free Days [ Time Frame: 30 days ]
    Does the use of inhaled volatile anesthetic-based sedation regimen improve participant ventilation outcomes after 30 days post enrollment, as compared to standard intravenous sedation regimen for 200 participants

  3. ICU-Free Days [ Time Frame: 30 days ]
    Does the use of inhaled volatile anesthetic-based sedation regimen improve participant time spent in ICU, 30 days post enrollment, as compared to standard intravenous sedation regimen for 128 participants

  4. Participant Quality of Life at 3 and 12 months after discharge [ Time Frame: 365 days ]
    Does the use of inhaled volatile anesthetic-based sedation regimen improve participant quality of life outcomes at 3 and 12 months post discharge as compared to standard intravenous sedation regimen for 144 participants. The EQ-5D questionnaire will be completed at both time points


Secondary Outcome Measures :
  1. Median Daily Oxygenation [ Time Frame: 3 days ]
    To evaluate participant median daily oxygenation (PaO2/FiO2) at 3 days post enrollment

  2. Adjunctive ARDS therapies [ Time Frame: 30 days ]
    To evaluate participant need for adjunctive ARDS therapies (prone, nitric oxide, paralysis, ECMO) during ICU stay

  3. Hospital-Free Days [ Time Frame: 60 days ]
    To evaluate the number of hospital-free days for participants, 60 days after enrollment

  4. Disability [ Time Frame: 365 days ]
    To evaluate participant disability at 3 and 12 months post discharge. The World Health Organization Disabiltity Assessment Score (WHODAS 2.0) will be completed at both timepoints. The scores assigned to each of the items - "none" (0), "mild" (1) "moderate" (2), "severe" (3) and "extreme" (4) - are summed. This method is referred to as simple scoring because the scores from each of the items are simply added up without recoding or collapsing of response categories; thus, there is no weighting of individual items.

  5. Cost Utility Analysis [ Time Frame: 365 days ]
    Quality of Life (QALY) assessment to be calculated using the EQ-5D, comparison costs at 3 and 12 months post discharge, costs associated with hospital stay, devices and sedative costs

  6. Cost Effectiveness Analysis [ Time Frame: 365 days ]
    Life Year Gained (LYG) to be calculated using the EQ-5D, total costs during hospitalization, and health care utilization for 1 year after discharge.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults ≥18 years of age
  2. Mechanically ventilated ≤ 48 hours
  3. Positive or possible COVID-19 disease

Exclusion Criteria:

  1. Contraindications to sedatives, such as propofol infusion syndrome or malignant hyperthermia;
  2. Known allergy to any of the ingredients or components of the investigational products; sevoflurane or isoflurane;
  3. Suspect or evidence of high intracranial pressure;
  4. One-lung ventilation or pneumonectomy;
  5. Ideal estimated tidal volume too low for delivery of inhaled agents. Target (6ml/kg) < 200ml;
  6. Use of inhaled prostacyclin which is contraindicated in the presence of a miniature vaporizer (i.e., Anesthesia Conserving Device). This agent has a high viscosity that leads to poor vaporization of the volatile agent. Other inhaled pulmonary vasodilators such as nitric oxide can be safely administered in the presence of miniature vaporizers. Use of prostacyclin is permissible with an anesthesia machine and MADM;
  7. Known pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04415060


Contacts
Layout table for location contacts
Contact: Angela Jerath, MD 416.480.6100 angela.jerath@sunnybrook.ca

Locations
Layout table for location information
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Contact: Oleksa Rewa, MD       rewa@ualberta.ca   
Principal Investigator: Oleksa Rewa, MD         
Canada, Ontario
London Health Sciences Centre - University Hospital
London, Ontario, Canada, N6A 5A5
Contact: Marat Slessarev, MD       Marat.Slessarev@lhsc.on.ca   
Principal Investigator: Marat Slessarev, MD         
London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada
Contact: Marat Slessarev, MD       Marat.Slessarev@lhsc.on.ca   
Principal Investigator: Marat Slessarav, MD         
Sub-Investigator: Claudio Martin, MD         
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5
Contact: Angela Jerath, MD    416.480.6100    angela.jerath@sunnybrook.ca   
Sub-Investigator: Brian Cuthbertson, MD         
Principal Investigator: Angela Jerath, MD         
University Health Network - Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Contact: Lorenzo del Sorbo, MD       Lorenzo.delSorbo@uhn.ca   
Canada, Quebec
Centre hospitalier de l'Université de Montréal
Montréal, Quebec, Canada, H2X 3E4
Contact: Francois-Martin Carrier, MD       francois-martin.carrier.chum@ssss.gouv.qc.ca   
Principal Investigator: Francois-Martin Carrier, MD         
Universite de Sherbrooke
Sherbrooke, Quebec, Canada, J1K 2R1
Contact: Francois Lamontange, MD       Francois.Lamontagne@USherbrooke.ca   
Principal Investigator: Francois Lamontange, MD         
Canada
University Health Network - Toronto Western Hopsital
Toronto, Canada, M5T 2S8
Contact: Ian Randall, MD       ian.randall@uhn.ca   
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Layout table for additonal information
Responsible Party: Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT04415060    
Other Study ID Numbers: 2149
First Posted: June 4, 2020    Key Record Dates
Last Update Posted: June 26, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sunnybrook Health Sciences Centre:
sedation
ICU
volatile anesthetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Critical Illness
Disease Attributes
Pathologic Processes
Sevoflurane
Isoflurane
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs